A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2018
At a glance
- Drugs ACH-0145228 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Achillion Pharmaceuticals
- 07 Nov 2018 According to an Achillion Pharmaceuticals media release, the company has announced that it plans to provide interim data from this trial on December 17, 2018.
- 03 Sep 2018 Status changed from recruiting to completed.
- 08 Aug 2018 According to an Achillion Pharmaceuticals media release, the dosing has been completed and the company expect to provide data and a strategic update in December 2018.